Industry Information

Cell Culture

Complete solutions for robust and efficient upstream processes

Improve productivity and reliability of your critical upstream operations by investing in the right cell culture technology solutions

What does it take to get a new biotech drug to market? The process development starts with culturing cells and requires the right technology to reliably and efficiently produce them. In addition, a capability to seamlessly move out of process development, into clinical trials, and from small to large-scale cGMP manufacturing, is essential.

The cell culture process requirements for biotechnology drugs have become increasingly challenging, with a drive for process intensification. Fed-batch, perfusion or continuous cell cultivation strategies are increasingly used to maximize productivity, leading to a growing demand for new approaches to bioreactor design, improving aeration and mixing, and to cell culture feed solutions.

Newer classes of therapy, such as cell and gene therapy, are now starting to show considerable promise; with the number of entities entering into clinical trial phases increasing significantly. Established laboratory scale approaches to cell culture start to be questionable when moving into clinical manufacturing that require cGMP with appropriate closed, automated and scalable systems. Scale is particularly important as therapies move into phase II and beyond, as batch sizes vary widely, depending on the number of patients and the dose required per patient.

When large quantities of adherent cells are needed, scaling out 2-dimensional cell growth systems like roller bottles and cell factories quickly limits possibilities, as they need a lot of manual operations. This makes them prone to high risk for contamination and other user errors. These systems don’t offer any cell culture monitoring options either, and thus, miss opportunities for control and automation, necessary for cGMP manufacturing.

The question often arises whether to change to suspension cell culture for growing cells to meet large-scale manufacturing demands. This requires either adapting the adherent cells to suspension, or moving to a different expression system. These changes are not trivial and can influence product quality, yield, cost and acceptance by regulatory agencies, all of which can have a serious impact on project timelines and budgets, and ultimately time to market. An alternative would be to scale-up the adherent cell process in well controlled, automated, fixed-bed bioreactors, or by using suitable microcarriers in stirred-tank production systems.

Regardless of what your path is, at Pall we have the right cell culture solution for you and your process. Our technologies are the complete and integrated solutions that increase your upstream process performance, while adding operational simplicity and improving reliability; whether you are growing adherent cells or suspension cells for gene therapy, cell therapy, vaccine or monoclonal antibody (mAb) manufacturing.

iCELLis® Bioreactors

Xpansion® Multiplate Bioreactors

Thank you for your inquiry. Someone will be in touch soon to discuss your requirements.

We have just sent you a verification email. Please confirm your email.

Thank you for your inquiry. Someone will be in touch soon to discuss your requirements.

Connect with us on our social media channels.

Give Biotech A Call

Country

Albania

Algeria

Argentina

Australia

Austria

Bangladesh

Belarus

Belgium

Bolivia

Bosnia and Herzegovina

Brazil

Bulgaria

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Czech Republic

Denmark

Dominican Republic

Ecuador

Egypt

El Salvador

Estonia

Finland

France

Germany

Greece

Guatemala

Hong Kong

Hungary

Iceland

India

Indonesia

Iraq

Ireland (Republic Of)

Israel

Italy

Japan

Jordan

Kazakhstan

Korea

Kuwait

Latvia

Lebanon

Lithuania

Macedonia

Malaysia

Malta

Mexico

Moldavia

Montenegro

Morocco

Netherlands

New Zealand

Nigeria

Norway

Oman

Pakistan

Panama

Paraguay

Peru

Philippines

Poland

Puerto Rico

Qatar

Romania

Russia

Saudi Arabia

Serbia

Singapore

Slovakia

Slovenia

South Africa

Spain

Sweden

Switzerland

Taiwan

Thailand

Trinidad

Tunisia

Turkey

USA

Ukraine

United Arab Emirates

United Kingdom

Uruguay

Venezuela

Vietnam

Yemen

World Headquarters: +1 (516) 484-3600

Share Biotech With The World

Find Biotech Locations

Region

Africa and Middle East

AsiaPac

Europe

Latin America and Caribbean

North America

Country

Pall Corporation is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste.